Despite enormous advances, management of multiple myeloma (MM) remains challenging.
Multiple factors impact the decision to treat or which regimen to use at MM …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed
multiple myeloma. The combination of the proteasome inhibitor carfilzomib with …

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical
studies has synergistic anti-myeloma activity when combined with bortezomib and …

We demonstrate a method for the prediction of chemotherapeutic response in patients using
only before-treatment baseline tumor gene expression data. First, we fitted models for whole …

Background Few effective treatments exist for patients with refractory or relapsed and
refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide …

Purpose To perform a critical analysis on the impact of depth of response in newly
diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 …

Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …